ArticleDigestive diseases and sciences2026
Impact of Type 2 Diabetes Mellitus on Liver Fibrosis and Hepatic Steatosis in Patients with Primary Biliary Cholangitis: A Longitudinal Study.
Article in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe prevalence of type 2 diabetes mellitus (T2DM) and its associated hepatic steatosis has surged with the obesity epidemic. The influence of T2DM on the natural history of primary biliary cholangitis (PBC) remains poorly characterized.
aimsThis study aims to assess the prevalence of T2DM in a PBC cohort and evaluate its impact on hepatic steatosis, liver fibrosis, and clinical outcomes.
methodsA retrospective analysis was performed. The presence of hepatic steatosis was defined by a controlled attenuation parameter (CAP) ≥ 285 dB/m, and clinically significant liver fibrosis was defined by a liver stiffness measurement (LSM) ≥ 8.5 kPa assessed using vibration-controlled transient elastography (VCTE). The cohort was further stratified into four subgroups: PBC with T2DM (PBC/T2DM), PBC without T2DM (PBC/non-T2DM), PBC with hepatic steatosis (PBC/steatosis), and PBC without hepatic steatosis (PBC/no steatosis). Group comparisons were performed using t-tests, chi-squared analyses, and Kaplan-Meier survival curves.
results562 patients with PBC were identified. The prevalence of T2DM was 14.8%. 158 (28%) patients had VCTE measurements. The PBC/T2DM sub-cohort was more likely to have concomitant hepatic steatosis compared to PBC/non-T2DM (54% vs 28%, p-value 0.010). The prevalence of clinically significant fibrosis was similar between these two groups (69% vs 52%, p-value 0.097). All-cause mortality rates were similar between PBC/T2DM vs PBC/non-T2DM (p-value 0.960) and PBC/steatosis vs PBC/no steatosis (p-value 0.895).
conclusionT2DM is a risk factor for the development of hepatic steatosis in patients with PBC; however, it does not increase the likelihood of clinically significant liver fibrosis or all-cause mortality.
Indexed as
Identifiers
41526575What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.